H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Aquestive Therapeutics Gains Buy Rating Amid Orphan Drug Exclusivity and Promising Product Pipeline
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
Express News | HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
Sector Update: Health Care Stocks Lower Thursday Afternoon
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Patients With Seizure Clusters Ages 2-5
